Plain-language summary

This Phase 2 trial is testing Enasidenib and Rituximab for people whose a type of T-cell lymphoma called AITL has come back or has not responded to previous treatment. The study measures how well this treatment works and monitors for side effects. It is available at 8 US locations across multiple states.

Who can join (key eligibility)

• Age 18 Years or older
• Lymphoma came back or did not respond to prior treatment
• Must be well enough for treatment (adequate performance status)
• May require specific number of prior treatments

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Enasidenib (DRUG): Enasidenib 100 mg daily on 28-day cycles. | Rituximab (DRUG): IV rituximab 375 mg/m² weekly for the first month, and monthly thereafter on 28-day cycles, for a total of four months of rituximab.

Drugs / treatments

Enasidenib, Rituximab

Treatment length

Ask the trial team for details

Visit frequency

Ask the trial team for details